logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
4/17/2020 8:36:44 AM Sangamo Therapeutics Appoints Mark McClung As EVP And Chief Business Officer
4/9/2020 8:05:06 AM Sangamo Therapeutics Announces Closing Of Previously Announced Sale Of Stock To Biogen
2/28/2020 7:11:21 AM Sangamo Therapeutics Q4 EPS $0.04 Vs Loss $0.18 Last Year
2/27/2020 4:11:32 PM Biogen And Sangamo Therapeutics Execute Global Licensing collaboration Agreement
2/12/2020 8:39:34 AM Sangamo Therapeutics Appoints John Markels To Board
12/9/2019 6:51:13 AM Sangamo Announces Preliminary Results From First 3 Patients In Phase 1/2 THALES Study
11/19/2019 7:07:56 AM Sangamo Therapeutics Reports UK Authorization Of Phase 1/2 Clinical Trial Evaluating CAR-Treg Cell Therapy TX200
11/1/2019 8:11:42 AM Sangamo Therapeutics Appoints Sung Lee As EVP And CFO
9/30/2019 4:54:12 PM Sangamo Therapeutics Appoints Bettina Cockroft As SVP And Chief Medical Officer
8/12/2019 7:42:55 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) FY20 Rev. Estimate To 55.1 M From 74.2 M
8/12/2019 7:42:39 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q4 20 Rev. Estimate To 9.5 M From 14.2 M
8/12/2019 7:42:29 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q3 20 Rev. Estimate To 9.2 M From 14.0 M
8/12/2019 7:42:16 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q2 20 Rev. Estimate To 9.2 M From 14.0 M
8/12/2019 7:41:57 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q1 20 Rev. Estimate To 27.2 M From 32.0 M
8/12/2019 7:41:29 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) FY19 Rev. Estimate To 61.3 M From 100 M
8/12/2019 7:38:44 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q4 19 Rev. Estimate To 18.9 M From 32.2 M